- Home
- ARCT vs ADCT Comparison
ARCT vs ADCT Comparison
Compare ARCT & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- ADCT
- Stock Information
- Founded
- ARCT 2013
- ADCT 2011
- Country
- ARCT United States
- ADCT Switzerland
- Employees
- ARCT N/A
- ADCT N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- ADCT Health Care
- Exchange
- ARCT Nasdaq
- ADCT Nasdaq
- Market Cap
- ARCT 298.3M
- ADCT 241.0M
- IPO Year
- ARCT N/A
- ADCT 2020
- Fundamental
- Price
- ARCT $12.10
- ADCT $3.48
- Analyst Decision
- ARCT Strong Buy
- ADCT Strong Buy
- Analyst Count
- ARCT 8
- ADCT 5
- Target Price
- ARCT $52.33
- ADCT $7.75
- AVG Volume (30 Days)
- ARCT 484.3K
- ADCT 853.5K
- Earning Date
- ARCT 08-04-2025
- ADCT 05-14-2025
- Dividend Yield
- ARCT N/A
- ADCT N/A
- EPS Growth
- ARCT N/A
- ADCT N/A
- EPS
- ARCT N/A
- ADCT N/A
- Revenue
- ARCT $143,680,000.00
- ADCT $75,817,000.00
- Revenue This Year
- ARCT N/A
- ADCT $9.19
- Revenue Next Year
- ARCT $39.32
- ADCT $16.27
- P/E Ratio
- ARCT N/A
- ADCT N/A
- Revenue Growth
- ARCT 15.38
- ADCT 10.49
- 52 Week Low
- ARCT $8.04
- ADCT $1.05
- 52 Week High
- ARCT $45.00
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- ARCT 48.75
- ADCT 72.87
- Support Level
- ARCT $11.51
- ADCT $3.26
- Resistance Level
- ARCT $13.27
- ADCT $3.85
- Average True Range (ATR)
- ARCT 0.82
- ADCT 0.35
- MACD
- ARCT 0.01
- ADCT 0.12
- Stochastic Oscillator
- ARCT 26.15
- ADCT 73.61
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).